WINTON GROUP Ltd Acquires 3,124 Shares of biote Corp. (NASDAQ:BTMD)

WINTON GROUP Ltd lifted its holdings in shares of biote Corp. (NASDAQ:BTMD) by 7.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 47,725 shares of the company’s stock after purchasing an additional 3,124 shares during the period. WINTON GROUP Ltd owned about 0.08% of biote worth $357,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC bought a new stake in biote in the 2nd quarter worth $42,000. Bailard Inc. bought a new stake in biote in the 2nd quarter worth $146,000. Rhumbline Advisers grew its holdings in biote by 104.2% in the 2nd quarter. Rhumbline Advisers now owns 28,225 shares of the company’s stock worth $211,000 after acquiring an additional 14,404 shares during the last quarter. Sanders Morris Harris LLC bought a new stake in biote in the 2nd quarter worth $585,000. Finally, Bank of New York Mellon Corp grew its holdings in biote by 59.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 94,318 shares of the company’s stock worth $705,000 after acquiring an additional 34,999 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.

Insider Activity

In other news, CFO Robert Charles Peterson sold 11,376 shares of biote stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $7.57, for a total transaction of $86,116.32. Following the sale, the chief financial officer now owns 32,874 shares of the company’s stock, valued at approximately $248,856.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 13.90% of the company’s stock.

biote Stock Down 2.3 %

Shares of biote stock opened at $5.88 on Thursday. The firm has a market cap of $364.77 million, a PE ratio of 53.45 and a beta of 0.94. biote Corp. has a 12-month low of $3.65 and a 12-month high of $8.44. The company’s fifty day simple moving average is $6.69 and its two-hundred day simple moving average is $6.41.

biote (NASDAQ:BTMD) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The business had revenue of $49.17 million for the quarter, compared to analyst estimates of $50.40 million. biote had a net margin of 3.67% and a negative return on equity of 20.92%. As a group, sell-side analysts expect that biote Corp. will post 0.52 earnings per share for the current fiscal year.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.